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Endocrine disruptors are defined by WHO as “exogenous compounds or mixtures that alter 
function(s) of the endocrine system and consequently cause adverse effects in an intact 
organism, or its progeny, or (sub)populations”.1 European Union (EU) laws on pesticides (plant 
protection products regulation [PPPR]) and biocide products regulation (BPR), enacted in 2009 
and 2012, respectively, place restrictions on the use of active substances with severe forms of 
toxicity, including carcinogenicity, mutagenicity, reproductive toxicity, and endocrine disruption. 
Chemicals with such properties will in the future not receive authorisation for placement on the 
market as active substances in pesticide or biocide products. Compared with earlier EU law, 
these legal provisions are innovative in two respects: first, for the first time, pesticides and 
biocides with endocrine-disrupting properties are regulated; second, those with severe toxicities 
are regulated solely on the basis of hazard identification, and not by risk assessment, as 
previously. Hazard identification pinpoints a potential threat to health (eg, a chemical), which is 
further analysed in a process of hazard characterisation in terms of additional features such as 
species sensitivities, dose-response relationships, and others. Risk assessment relates the 
likelihood that an effect occurs to exposures experienced under different circumstances.2 This 
development requires that scientific criteria for the identification of endocrine disruptors are 
developed, and the European Commission (EC) was obliged by law to publish such scientific 
criteria within the context of PPPR and BPR by 2013. 
Commercial interests have strongly argued against hazard-based cut-off criteria for endocrine 
disruptors, which resulted in the EC conducting an impact assessment before defining the 
endocrine disruptor criteria.3 Inevitably, this challenge has delayed the publication of criteria to 
such an extent that Sweden and other EU member states brought a case against the EC for not 
establishing the criteria. In December, 2015, the European Court of Justice judged that the EC 
acted unlawfully in failing to publish the criteria, and that an impact assessment was not 
necessary for their development.4 This judgment has been followed by a resolution adopted by 
the European Parliament on June 8, 2016. This resolution stresses that the criteria can only be 
carried out on the basis of scientific data related to the endocrine system, independently of any 
other consideration, particularly economic ones. Also, it calls on the Commission to immediately 
adopt hazard-based scientific criteria for the determination of endocrine-disrupting properties. 
At the time of publication, the EC has not released the endocrine disruptor criteria and continues 
to justify this delay with reference to a controversy within the scientific community.5 However, 
we have recently shown that the controversy is not about the basics of endocrine disruptor 
science, but rather is the result of a lack of distinction between hazard identification and risk 
assessment (which is not required for the identification of endocrine disruptors as defined in the 
laws on pesticides and biocides).2 Very recently, this confusion was resolved, and a consensus 
among the scientists engaged in the previous debate has emerged, with all involved now 
accepting that the regulatory decision-making required in EU laws on pesticides and biocides 
involves hazard identification.6 We have also shown that endocrine disruptors can be identified 
through a scientific strategy analogous to that implemented for carcinogens by the International 
Agency for Research on Cancer (IARC; part of WHO).2 The first step in risk assessment is to 
identify whether a chemical or a mixture belongs to a given class of hazards, such as carcinogens. 
IARC identifies carcinogens and categorises the degree of confidence in this identification 
Published in : The Lancet. Diabetes & Endocrinology (2016), vol. 4, pp. 643–646 
DOI:10.1016/S2213-8587(16)30121-8 




without regard to potency. No one would suggest making the definition of carcinogens 
dependent on an impact assessment, and the same should apply to endocrine disruptors. 
Although a great deal is known about how hormones affect health and disease, there remains 
much to learn. Similarly, we know a great deal about how some manufactured chemicals can 
cause adverse effects in human beings, farm animals, and wildlife by interfering with hormones.7 
Researchers have shown that endocrine disruptors can produce epigenetic modifications and 
transgenerational effects.8 Such scientific evidence must be considered appropriately with 
respect to its implications for human health today and for future generations. Robust science at 
the leading edge allows us to discriminate among the known, the possible, and the unknown. 
Therefore, the decision taken by the EC should be based on what we know now, and allow 
incorporation of new information as it becomes available. 
In a roadmap that the EC released in 2014 to define the parameters of impact assessment, four 
different options for defining regulatory criteria for endocrine disruptors were proposed.9 The 
first does not provide defining criteria, and is therefore not operable. Two options (labelled 2 
and 3) rely on the WHO definition of endocrine disruptors; option 2 defines a single category of 
endocrine disruptors, whereas option 3 further identifies suspected endocrine disruptors and 
endocrine- active substances (figure). Such categories, based on level of evidence, are consistent 
with those used in the EU for carcinogens, mutagens, and reprotoxicants, which are hazards of 
equivalent concern to endocrine disruptors. Moreover, option 3 provides the necessary 
characteristics that will allow for incorporation of new data as it becomes available, which might 
trigger revised categorisations (figure). The majority of responders to the public consultation 
initiated by the EC about endocrine disruptor identification criteria were clearly in favour of 
option 3.10 The Endocrine Society, the world’s largest organisation devoted to research on 
hormones and the clinical care of endocrine disorders, also supports this option.11 An 
assessment of the strength of the evidence has also been used in studies on the cost of managing 
health consequences of endocrine disruptors in the EU; with more than 99% probability, this 
cost exceeds €160 billion per year.12 
The last option (option 4; figure) uses a binary definition (endocrine disruptors or non-
endocrine disruptors) and incorporates potency as a criterion. The idea of including potency 
was initiated by UK and German authorities. Mindful of the potential economic effect on industry 
of regulating substances with ED properties in a hazard-based system, the stated intention was 
to only assign the endocrine disruptor identifier to substances of high potency and where the 
endocrine disruptor property is a prominent feature of the hazard profile.13 Potency, however, is 
not mentioned in the accepted WHO definition1 and has been deemed irrelevant for the 
identification of endocrine disruptors.2 Potency is quite complex to apply as a criterion and 
scientifically indefensible because a single chemical might seem differently potent depending on 
the endpoint and the testing conditions (figure). Potency is measured by a dose-response 
function; however, the variability of the response and the corresponding likelihood of 
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Figure. Two proposed options for identification of EDs in the European Union. 
 
In a 2014 roadmap, the European Commission has proposed criteria for ED identification through four 
options; here we show option 3 (A) and option 4 (B). From summer, 2016, EDs will be identified based on 
one option or the other. Option 3 identifies endocrine-inactive substances and three ED categories based 
on the level of evidence; it allows for further revision based on new scientific information. Option 4 uses 
potency as a criterion and identifies only one ED category; its application implies further questions about 
selected endpoints, cutoff criteria, and predictive value. In panel B, the four symbols arbitrarily denote 
different levels of potency of a given chemical depending on the studied endpoint. 
ED = endocrine disruptor. IPCS = International Programme on Chemical Safety. 
 
Historically, diethylstilbestrol and thalidomide are notable examples. These drugs were 
prescribed for pregnant women without any adverse effects being noted. However, the children 
of treated women showed adverse effects—either at the time of birth, or several years later. In 
these cases, the prediction of negligible potency from some in-vivo testing gave physicians the 
confidence to prescribe these drugs, but they were tragically missing crucial data for 
developmental issues. In a recent position statement about EU regulation of endocrine 
disruptors, the Endocrine Society recommended the exclusion of potency from identification 
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criteria.11 Similarly, the consensus statement from the scientists engaged in the previous debate 
over scientific principles for the identification of endocrine disruptors states that potency 
considerations have no place in the hazard identification process for endocrine disruptors.6 
The current scientific consensus on the relevance of the WHO definition of endocrine 
disruptors,1 the irrelevance of potency for the identification of endocrine disruptors,2,6 and the 
inapplicability of impact assessment studies to provide scientific definition of endocrine 
disruptors2,11 all point to the same conclusion. As scientists, we believe that science provides all 
necessary arguments towards implementation of relevant criteria to identify endocrine 
disruptors. Such criteria are consistent with an option already formulated by the EC: option 3 of 
the EC roadmap. Public health urgently deserves science-based regulations. 
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